



Financial Tear Sheet

Corporate Profile

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

Primary IR Contact

Jennifer Robinson

Phone: 617-674-9873

E-mail:

jrobinson@rapharma.com

Stock Performance

RARX (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$9.55**

Change (%) ▲
0.37 (4.03%)

Volume 347,394

52 Week Low \$4.78

Market Cap \$296,629,163

Rolling EPS -2.51

PE Ratio 0



Shares Outstanding 32,312,545

Data as of June 19, 2018 4:00 p.m. ET

Recent Headlines & Events

June 15, 2018 - 7:00 a.m.

[Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association](#)

June 5, 2018 - 7:00 a.m.

[Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology](#)

May 31, 2018 - 7:00 a.m.

[Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference](#)

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: **1.8**



Sell

Strong Buy

Unable to fulfill request.

SEC Filings

Filing Date	Form
-------------	------

Corporate Governance

Robert Heft
Director

06/07/18

8-K

Jason Lettmann

05/09/18

424B5

Director

05/09/18

8-K

Ed Mathers

05/09/18

S-8

Director

Tim Pearson

Director

Rajeev Shah

Director

Peter Tuxen-Bisgaard

Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	124	224.17	99.1	32,023,898
Mutual Fund	124	29.38	12.3	3,986,803
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
New Enterprise Associates (NEA)	5,493,636	17.0	2,000,000	March 31, 2018
RA Capital Management, LLC	3,851,808	11.9	2,500,000	March 31, 2018
Wellington Management Company, LLP	2,907,497	9.0	140,254	March 31, 2018
Morgenthaler Ventures	2,745,846	8.5	2,745,846	October 25, 2016
Novartis AG	1,615,996	5.0	-636,161	December 31, 2017
Novo Holdings A/S	1,465,838	4.5	-565,724	March 31, 2018
Consonance Capital Management LP	1,454,761	4.5	1,454,761	March 31, 2018
Plain (Plain)	1,320,657	4.1	1,320,657	October 25, 2016
Lightstone Ventures, L.P.	1,320,655	4.1	1,320,655	December 31, 2016
BlackRock Institutional Trust Company, N.A.	1,001,394	3.1	195,906	March 31, 2018

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)